A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer
The study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with Anlotinib in patients whose disease has progressed following first-line EGFR-TKIs treatment.
NSCLC
DRUG: Sunvozertinib combination with Anlotinib
ORR, Objective response rate (ORR) as assessed by the investigator according to RECIST 1.1 criteria., initiate from first dose until the date of confirmed response, assessed up to 24 weeks
PFS, PFS as assessed by the investigator according to RECIST 1.1, initiate from first dose, every 6 weeks until PD or study close, an average of 1 year|OS, initiate from first dose to death from any cause, through study completion, an average of 1.5 years|DoR, The period from the first judgment of CR or PR to PD, an average of 1 year|AE, TRAE as assessed by the investigator according to CTCAE 5.0, through study completion, an average of 1 year
The study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with Anlotinib in patients whose disease has progressed following first-line EGFR-TKIs treatment.